GlycoBac, LLC

GlycoBac has developed a sensitive assay for infectious Sf-rhabdovirus particles using our proprietary Sf-RVN cell line. GlycoBac has partnered with MilliporeSigma to facilitate the distribution of our Sf-RVN cell line for commercial vaccine and gene therapy vector production. In addition to distributing Sf-RVN cells through a cGMP cell bank, MilliporeSigma will offer a chemically defined medium formulation specially designed for Sf-RVN cells.